{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:26:48Z","timestamp":1776137208237,"version":"3.50.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"DOI":"10.1007\/s11934-026-01336-1","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:34:53Z","timestamp":1776134093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancements in the Treatment and Management of Voiding Dysfunction in Individuals with Spina Bifida"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8893-4286","authenticated-orcid":false,"given":"Jonathan T.","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"1336_CR1","doi-asserted-by":"publisher","unstructured":"Briggs VG. Population Estimates of People with Spina Bifida in the United States in 2020. Epidemiology; 2022 [cited 2026 Feb 24]. Available from: https:\/\/doi.org\/10.1101\/2022.02.03.22268639","DOI":"10.1101\/2022.02.03.22268639"},{"issue":"1","key":"1336_CR2","doi-asserted-by":"publisher","first-page":"e2301","DOI":"10.1002\/bdr2.2301","volume":"116","author":"EB Stallings","year":"2024","unstructured":"Stallings EB, Isenburg JL, Rutkowski RE, Kirby RS, Nembhard WN, Sandidge T, et al. National population-based estimates for major birth defects, 2016\u20132020. Birth Defects Res. 2024;116(1):e2301. https:\/\/doi.org\/10.1002\/bdr2.2301.","journal-title":"Birth Defects Res"},{"key":"1336_CR3","unstructured":"Urology Guideline-. Spina Bifida Association. [cited 2026 Feb 24]. Available from: https:\/\/www.spinabifidaassociation.org\/blog\/urology-guideline\/"},{"issue":"4","key":"1336_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/0090-4295(77)90168-6","volume":"10","author":"SB Bauer","year":"1977","unstructured":"Bauer SB, Labib KB, Dieppa RA, Retik AB. Urodynamic evaluation of boy with myelodysplasia and incontinence stuart. Urology. 1977;10(4):354\u201362. https:\/\/doi.org\/10.1016\/0090-4295(77)90168-6.","journal-title":"Urology"},{"issue":"7","key":"1336_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S1474-4422(15)00070-8","volume":"14","author":"JN Panicker","year":"2015","unstructured":"Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720\u201332. https:\/\/doi.org\/10.1016\/S1474-4422(15)00070-8.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1336_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s004310100741","volume":"160","author":"JD Van Gool","year":"2001","unstructured":"Van Gool JD, Dik P, De Jong TPVM. Bladder-sphincter dysfunction in myelomeningocele. Eur J Pediatrics. 2001;160(7):414\u201320. https:\/\/doi.org\/10.1007\/s004310100741.","journal-title":"Eur J Pediatrics"},{"key":"1336_CR7","doi-asserted-by":"crossref","unstructured":"Yeung CK, Barker GM, Lackgren G. Pathophysiology of bladder dysfunction. In: Pediatric Urology. Second Edition. Saunders; 2010. pp. 353\u201365.","DOI":"10.1016\/B978-1-4160-3204-5.00027-X"},{"issue":"5","key":"1336_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40272-017-0249-x","volume":"19","author":"P Kroll","year":"2017","unstructured":"Kroll P. Pharmacotherapy for Pediatric Neurogenic Bladder. Pediatr Drugs. 2017;19(5):463\u201378. https:\/\/doi.org\/10.1007\/s40272-017-0249-x.","journal-title":"Pediatr Drugs"},{"issue":"6S","key":"1336_CR9","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.juro.2011.01.025","volume":"185","author":"P Metcalfe","year":"2011","unstructured":"Metcalfe P, Gray D, Kiddoo D. Management of the Urinary Tract in Spina Bifida Cases Varies With Lesion Level and Shunt Presence. J Urol. 2011;185(6S):2547\u201351. https:\/\/doi.org\/10.1016\/j.juro.2011.01.025.","journal-title":"J Urol"},{"issue":"4","key":"1336_CR10","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1097\/JU.0000000000000334","volume":"202","author":"JW Brock","year":"2019","unstructured":"Brock JW, Thomas JC, Baskin LS, Zderic SA, Thom EA, Burrows PK, et al. Effect of Prenatal Repair of Myelomeningocele on Urological Outcomes at School Age. J Urol. 2019;202(4):812\u20138. https:\/\/doi.org\/10.1097\/JU.0000000000000334.","journal-title":"J Urol"},{"issue":"6","key":"1336_CR11","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/nau.24422","volume":"39","author":"I Ehr\u00e9n","year":"2020","unstructured":"Ehr\u00e9n I, Lindbo L, Gabrielsson H, Bendt M, Seiger \u00c5. Voiding conditions, renal and bowel function in a cohort of adults with spina bifida. Neurourol Urodyn. 2020;39(6):1796\u2013802. https:\/\/doi.org\/10.1002\/nau.24422.","journal-title":"Neurourol Urodyn"},{"issue":"10099","key":"1336_CR12","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S0140-6736(17)32282-1","volume":"390","author":"DA Diamond","year":"2017","unstructured":"Diamond DA, Chan IHY, Holland AJA, Kurtz MP, Nelson C, Estrada CR, et al. Advances in paediatric urology. Lancet. 2017;390(10099):1061\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)32282-1.","journal-title":"Lancet"},{"issue":"3","key":"1336_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0022-5347(17)61055-3","volume":"107","author":"J Lapides","year":"1972","unstructured":"Lapides J, Diokno AC, Silber SJ, Lowe BS, Clean. Intermittent Self-Catheterization in the Treatment of Urinary Tract Disease. J Urol. 1972;107(3):458\u201361. https:\/\/doi.org\/10.1016\/S0022-5347(17)61055-3.","journal-title":"J Urol"},{"issue":"2","key":"1336_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00467-023-06064-z","volume":"39","author":"N Brownrigg","year":"2024","unstructured":"Brownrigg N, Lorenzo AJ, Rickard M, Dos Santos J. The urological evaluation and management of neurogenic bladder in children and adolescents\u2014what every pediatric nephrologist needs to know. Pediatr Nephrol. 2024;39(2):409\u201321. https:\/\/doi.org\/10.1007\/s00467-023-06064-z.","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"1336_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jpurol.2022.10.016","volume":"19","author":"RJ Fairchild","year":"2023","unstructured":"Fairchild RJ, Aksenov LI, Hobbs KT, Krischak MK, Kaplan SJ, Purves JT, et al. Medical management of neurogenic bladder in patients with spina bifida: A scoping review. J Pediatr Urol. 2023;19(1):55\u201363. https:\/\/doi.org\/10.1016\/j.jpurol.2022.10.016.","journal-title":"J Pediatr Urol"},{"issue":"7","key":"1336_CR16","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/nau.22206","volume":"31","author":"LMO De Kort","year":"2012","unstructured":"De Kort LMO, Bower WF, Swithinbank LV, Marschall-Kehrel D, De Jong TPVM, Bauer SB. The management of adolescents with neurogenic urinary tract and bowel dysfunction. Neurourol Urodyn. 2012;31(7):1170\u20134. https:\/\/doi.org\/10.1002\/nau.22206.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"1336_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11255-013-0423-1","volume":"45","author":"M Baek","year":"2013","unstructured":"Baek M, Kang JY, Jeong J, Kim DK, Kim KM. Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia. Int Urol Nephrol. 2013;45(3):703\u20139. https:\/\/doi.org\/10.1007\/s11255-013-0423-1.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1336_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ucl.2010.06.009","volume":"37","author":"A Mourtzinos","year":"2010","unstructured":"Mourtzinos A, Stoffel JT. Management Goals for the Spina Bifida Neurogenic Bladder: A Review from Infancy to Adulthood. Urol Clin North Am. 2010;37(4):527\u201335. https:\/\/doi.org\/10.1016\/j.ucl.2010.06.009.","journal-title":"Urol Clin North Am"},{"issue":"4","key":"1336_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/nau.20507","volume":"27","author":"KM Giramonti","year":"2008","unstructured":"Giramonti KM, Kogan BA, Halpern LF. The effects of anticholinergic drugs on attention span and short-term memory skills in children. Neurourol Urodyn. 2008;27(4):315\u20138. https:\/\/doi.org\/10.1002\/nau.20507.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1336_CR20","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/j.juro.2013.06.036","volume":"190","author":"PW Veenboer","year":"2013","unstructured":"Veenboer PW, Huisman J, Chrzan RJ, Kuijper CF, Dik P, De Kort LMO, et al. Behavioral Effects of Long-Term Antimuscarinic Use in Patients with Spinal Dysraphism: A Case Control Study. J Urol. 2013;190(6):2228\u201332. https:\/\/doi.org\/10.1016\/j.juro.2013.06.036.","journal-title":"J Urol"},{"issue":"1","key":"1336_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41598-020-80211-6","volume":"11","author":"E Ghezzi","year":"2021","unstructured":"Ghezzi E, Chan M, Kalisch Ellett LM, Ross TJ, Richardson K, Ho JN, et al. The effects of anticholinergic medications on cognition in children: a systematic review and meta-analysis. Sci Rep. 2021;11(1):219. https:\/\/doi.org\/10.1038\/s41598-020-80211-6. PubMed PMID: 33420226; PubMed Central PMCID: PMC7794471.","journal-title":"Sci Rep"},{"issue":"3","key":"1336_CR22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11884-016-0371-6","volume":"11","author":"RM Sturm","year":"2016","unstructured":"Sturm RM, Cheng EY. The Management of the Pediatric Neurogenic Bladder. Curr Bladder Dysfunct Rep. 2016;11(3):225\u201333. https:\/\/doi.org\/10.1007\/s11884-016-0371-6.","journal-title":"Curr Bladder Dysfunct Rep"},{"issue":"3 Part 1","key":"1336_CR23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0022-5347(01)62828-3","volume":"160","author":"G Buyse","year":"1998","unstructured":"Buyse G, Waldeck K, Verpoorten C, Bjork H, Casaer P, Andersson KE. Intravesical oxybutynin for, neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol. 1998;160(3 Part 1):892\u20136. https:\/\/doi.org\/10.1016\/S0022-5347(01)62828-3.","journal-title":"J Urol"},{"issue":"5","key":"1336_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/nau.22755","volume":"35","author":"A Schr\u00f6der","year":"2016","unstructured":"Schr\u00f6der A, Albrecht U, Schnitker J, Reitz A, Stein R. Efficacy, safety, and tolerability of intravesically administered 0.1% oxybutynin hydrochloride solution in adult patients with neurogenic bladder: A randomized, prospective, controlled multi-center trial. Neurourol Urodyn. 2016;35(5):582\u20138. https:\/\/doi.org\/10.1002\/nau.22755.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1336_CR25","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/nau.22560","volume":"34","author":"M Humblet","year":"2015","unstructured":"Humblet M, Verpoorten C, Christiaens MH, Hirche H, Jansen K, Buyse G, et al. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: With special reference to age-dependent parameters: Long-Term Outcome of Intravesical Oxybutynin in Children. Neurourol Urodynam. 2015;34(4):336\u201342. https:\/\/doi.org\/10.1002\/nau.22560.","journal-title":"Neurourol Urodynam"},{"issue":"2","key":"1336_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/bju.70058","volume":"137","author":"M Buzzi","year":"2026","unstructured":"Buzzi M, Epstein J, Hatem Z, Juge N, Mazeaud C, Lemelle J, et al. Intravesical oxybutynin for bladder capacity in children with spina bifida: the \u2018Place de l\u2019OXybutynine Intrav\u00e9sicale chez le Patient Enfant Neurologique\u2019 (POXIPEN) trial protocol. BJU Int. 2026;137(2):390\u20138. https:\/\/doi.org\/10.1111\/bju.70058.","journal-title":"BJU Int"},{"key":"1336_CR27","doi-asserted-by":"publisher","first-page":"756582","DOI":"10.3389\/fphar.2021.756582","volume":"12","author":"D Zhang","year":"2021","unstructured":"Zhang D, Sun F, Yao H, Bao X, Wang D, Cui Y, et al. The Efficacy and Safety of Mirabegron for the Treatment of Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Meta-analysis. Front Pharmacol. 2021;12:756582. https:\/\/doi.org\/10.3389\/fphar.2021.756582. PubMed PMID: 34867373; PubMed Central PMCID: PMC8636815.","journal-title":"Front Pharmacol"},{"issue":"4","key":"1336_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40272-021-00452-4","volume":"23","author":"SJ Keam","year":"2021","unstructured":"Keam SJ, Mirabegron. Pediatric First Approval. Pediatr Drugs. 2021;23(4):411\u20135. https:\/\/doi.org\/10.1007\/s40272-021-00452-4.","journal-title":"Pediatr Drugs"},{"issue":"8","key":"1336_CR29","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s00345-018-2576-0","volume":"37","author":"JS Park","year":"2019","unstructured":"Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW. Efficacy and safety of mirabegron, a \u03b23-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019;37(8):1665\u201370. https:\/\/doi.org\/10.1007\/s00345-018-2576-0.","journal-title":"World J Urol"},{"issue":"6","key":"1336_CR30","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1002\/nau.24657","volume":"40","author":"M Baka-Ostrowska","year":"2021","unstructured":"Baka-Ostrowska M, Bolong DT, Persu C, T\u00f8ndel C, Steup A, Lademacher C, et al. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open\u2010label, phase 3, dose\u2010titration study. Neurourol Urodyn. 2021;40(6):1490\u20139. https:\/\/doi.org\/10.1002\/nau.24657.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"1336_CR31","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/JU.0000000000002361","volume":"207","author":"JK Kim","year":"2022","unstructured":"Kim JK, De Jesus MJ, Lee MJ, Dos Santos J, Dy JS, Ming JM, et al. \u03b23-Adrenoceptor Agonist for the Treatment of Bladder Dysfunction in Children: A Systematic Review and Meta-Analysis. J Urol. 2022;207(3):524\u201333. https:\/\/doi.org\/10.1097\/JU.0000000000002361.","journal-title":"J Urol"},{"key":"1336_CR32","unstructured":"FDA approves vibegron for. overactive bladder | Urology Times. [cited 2026 Mar 1]. Available from: https:\/\/www.urologytimes.com\/view\/fda-approves-vibegron-for-overactive-bladder"},{"issue":"17","key":"1336_CR33","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s40265-018-1006-3","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ, Vibegron. First Global Approval. Drugs. 2018;78(17):1835\u20139. https:\/\/doi.org\/10.1007\/s40265-018-1006-3.","journal-title":"Drugs"},{"issue":"9","key":"1336_CR34","doi-asserted-by":"publisher","first-page":"e0290685","DOI":"10.1371\/journal.pone.0290685","volume":"18","author":"S Yamamoto","year":"2023","unstructured":"Yamamoto S, Kusabuka H, Matsuzawa A, Maruyama I, Yamazaki T. Vibegron shows high selectivity and potent agonist activity for \u03b23-adrenoceptors, irrespective of receptor density. PLoS ONE. 2023;18(9):e0290685. . https:\/\/doi.org\/10.1371\/journal.pone.0290685","journal-title":"PLoS ONE"},{"issue":"13","key":"1336_CR35","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1080\/14656566.2022.2126311","volume":"23","author":"S Gleicher","year":"2022","unstructured":"Gleicher S, Sebesta EM, Reynolds WS, Dmochowski R. Vibegron for the treatment of overactive bladder: a comprehensive update. Expert Opin Pharmacother. 2022;23(13):1479\u201384. https:\/\/doi.org\/10.1080\/14656566.2022.2126311.","journal-title":"Expert Opin Pharmacother"},{"issue":"49","key":"1336_CR36","doi-asserted-by":"publisher","first-page":"e46109","DOI":"10.1097\/MD.0000000000046109","volume":"104","author":"WZ Bai","year":"2025","unstructured":"Bai WZ, Zhou SY, Mou YY, Peng L, Li LL. An updated meta-analysis of head-to-head trials comparing the efficacy, safety, and adherence of mirabegron and vibegron in overactive bladder. Medicine. 2025;104(49):e46109. https:\/\/doi.org\/10.1097\/MD.0000000000046109.","journal-title":"Medicine"},{"issue":"11","key":"1336_CR37","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.21037\/tp-2025-573","volume":"14","author":"H Ikeda","year":"2025","unstructured":"Ikeda H, Watanabe Y, Ohtomo Y, Miyano H, Fujinaga S, Gonda Y, et al. Safety and efficacy of vibegron in pediatric patients with treatment-resistant nocturnal enuresis: a multicenter retrospective study. Transl Pediatr. 2025;14(11):2955\u201367. https:\/\/doi.org\/10.21037\/tp-2025-573. PubMed PMID: 41367527; PubMed Central PMCID: PMC12683454.","journal-title":"Transl Pediatr"},{"issue":"5","key":"1336_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jpurol.2022.07.012","volume":"18","author":"T Kitta","year":"2022","unstructured":"Kitta T, Chiba H, Kon M, Higuchi M, Kusakabe N, Ouchi M, et al. Urodynamic evaluation of the efficacy of vibegron, a new \u03b23-adrenergic receptor agonist, on lower urinary tract function in children and adolescents with overactive bladder. J Pediatr Urol. 2022;18(5):563\u20139. https:\/\/doi.org\/10.1016\/j.jpurol.2022.07.012.","journal-title":"J Pediatr Urol"},{"issue":"4","key":"1336_CR39","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/nau.25163","volume":"42","author":"T Hyuga","year":"2023","unstructured":"Hyuga T, Tanabe K, Kubo T, Nakamura S, Nakai H, Moriya K. Vibegron shows high efficacy in pediatric patients with refractory daytime urinary incontinence. Neurourol Urodyn. 2023;42(4):794\u20138. https:\/\/doi.org\/10.1002\/nau.25163.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"1336_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/iju.14720","volume":"29","author":"K Aoki","year":"2022","unstructured":"Aoki K, Momose H, Gotoh D, Morizawa Y, Hori S, Nakai Y, et al. Video-urodynamic effects of vibegron, a new selective \u03b23\u2010adrenoceptor agonist, on antimuscarinic\u2010resistant neurogenic bladder dysfunction in patients with spina bifida. Int J Urol. 2022;29(1):76\u201381. https:\/\/doi.org\/10.1111\/iju.14720.","journal-title":"Int J Urol"},{"key":"1336_CR41","doi-asserted-by":"publisher","first-page":"100412","DOI":"10.1016\/j.ijso.2021.100412","volume":"37","author":"R Nasution","year":"2021","unstructured":"Nasution R, Husein A, Adhyatma KP. Efficacy and safety of mirabegron in pediatric population: A systematic review. Int J Surg Open. 2021;37:100412. https:\/\/doi.org\/10.1016\/j.ijso.2021.100412.","journal-title":"Int J Surg Open"},{"key":"1336_CR42","unstructured":"A Study of Vibegron in Pediatric Participants 2 Years to Less Than. (<) 18 Years of age with NDO and on CIC | TrialScreen. [cited 2026 Mar 1]. Available from: https:\/\/app.trialscreen.org\/trials\/phase-2-3-neurogenic-detrusor-overactivity-vibegron-pediatric-participants-trial-nct05491525"},{"key":"1336_CR43","unstructured":"Study on the safety and effectiveness of vibegron for children aged 2 to 17 with Neurogenic bladder overactivity using clean intermittent catheterization. [cited 2026 Mar 1]. Available from: https:\/\/clinicaltrials.eu\/trial\/study-on-the-safety-and-effectiveness-of-vibegron-for-children-aged-2-to-17-with-neurogenic-bladder-overactivity-using-clean-intermittent-catheterization\/"},{"issue":"4","key":"1336_CR44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.juro.2016.11.101","volume":"197","author":"F Morin","year":"2017","unstructured":"Morin F, Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol. 2017;197(4):1158\u201363. https:\/\/doi.org\/10.1016\/j.juro.2016.11.101.","journal-title":"J Urol"},{"issue":"8","key":"1336_CR45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00228-025-03855-1","volume":"81","author":"W Huang","year":"2025","unstructured":"Huang W, Zheng X, Luo J, Chen Y, Xu Y. Comparative efficacy and adverse effects of \u03b23-agonists and antimuscarinics in overactive bladder: a network and component network meta-analysis. Eur J Clin Pharmacol. 2025;81(8):1217\u201327. https:\/\/doi.org\/10.1007\/s00228-025-03855-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1336_CR46","doi-asserted-by":"publisher","first-page":"1407009","DOI":"10.3389\/fped.2024.1407009","volume":"12","author":"BT Frainey","year":"2024","unstructured":"Frainey BT, Clayton DB. OnabotulinumtoxinA is now an important tool for managing pediatric neurogenic lower urinary tract dysfunction. Front Pediatr. 2024;12:1407009. https:\/\/doi.org\/10.3389\/fped.2024.1407009.","journal-title":"Front Pediatr"},{"issue":"1","key":"1336_CR47","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/nau.24588","volume":"40","author":"PF Austin","year":"2021","unstructured":"Austin PF, Franco I, Dobremez E, Kroll P, Titanji W, Geib T, et al. OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children. Neurourol Urodyn. 2021;40(1):493\u2013501. https:\/\/doi.org\/10.1002\/nau.24588.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"1336_CR48","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/ans.19309","volume":"95","author":"G He","year":"2025","unstructured":"He G, Shen N, Feng S. Botulinum toxin A for the treatment of neurogenic bladder in children: a systematic review and meta-analysis. ANZ J Surg. 2025;95(6):1115\u201321. https:\/\/doi.org\/10.1111\/ans.19309.","journal-title":"ANZ J Surg"},{"key":"1336_CR49","doi-asserted-by":"publisher","unstructured":"Softness KA, Thaker H, Theva D, Rajender A, Cilento BG, Bauer SB, Onabotulinumtoxin A (Botox), editors. A reasonable alternative for refractory neurogenic bladder dysfunction in children and young adults. Neurourology and Urodynamics. 2021;40(8):1981\u20138. https:\/\/doi.org\/10.1002\/nau.24778","DOI":"10.1002\/nau.24778"},{"issue":"2","key":"1336_CR50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/JU.0000000000000540","volume":"203","author":"S Naqvi","year":"2020","unstructured":"Naqvi S, Clothier J, Wright A, Garriboli M. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A. J Urol. 2020;203(2):413\u20139. https:\/\/doi.org\/10.1097\/JU.0000000000000540.","journal-title":"J Urol"},{"issue":"4","key":"1336_CR51","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1097\/JU.0000000000003157","volume":"209","author":"I Franco","year":"2023","unstructured":"Franco I, Hoebeke PB, Dobremez E, Titanji W, Geib T, Jenkins B, et al. Long-term Safety and Tolerability of Repeated Treatments With OnabotulinumtoxinA in Children With Neurogenic Detrusor Overactivity. J Urol. 2023;209(4):774\u201384. https:\/\/doi.org\/10.1097\/JU.0000000000003157.","journal-title":"J Urol"},{"issue":"2","key":"1336_CR52","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jpurol.2013.10.011","volume":"10","author":"V Figueroa","year":"2014","unstructured":"Figueroa V, Romao R, Pippi Salle JL, Koyle MA, Braga LHP, B\u00e4gli DJ, et al. Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: Effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures. J Pediatr Urol. 2014;10(2):368\u201373. https:\/\/doi.org\/10.1016\/j.jpurol.2013.10.011.","journal-title":"J Pediatr Urol"},{"issue":"6","key":"1336_CR53","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/nau.24962","volume":"41","author":"DK Bowen","year":"2022","unstructured":"Bowen DK, Meyer T, Rosoklija I, Sturm R, Chu DI, Cheng EY, et al. Botulinum toxin in patients at-risk for bladder augmentation: Durable impact or kicking the can? Neurourol Urodyn. 2022;41(6):1406\u201313. https:\/\/doi.org\/10.1002\/nau.24962.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"1336_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/nau.24792","volume":"41","author":"T Silva","year":"2022","unstructured":"Silva T, Horliana T, Malavazzi ACR, Santos TCS, Gon\u00e7alves EM, Fernandes MLL. Efficacy and safety of electrical stimulation in the treatment of neurogenic bladder dysfunction in myelomeningocele\u2014Systematic review of randomized clinical trials. Neurourol Urodyn. 2022;41(1):91\u2013101. https:\/\/doi.org\/10.1002\/nau.24792.","journal-title":"Neurourol Urodyn"},{"issue":"S 1","key":"1336_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1055\/s-2008-1071209","volume":"7","author":"D Marshall","year":"1997","unstructured":"Marshall D, Boston V. Altered Bladder and Bowel Function Following Cutaneous Electrical Field Stimulation in Children with Spina Bifida - Interim Results of a Randomized Double-Blind Placebo-Controlled Trial. Eur J Pediatr Surg. 1997;7(S 1):41\u20133. https:\/\/doi.org\/10.1055\/s-2008-1071209.","journal-title":"Eur J Pediatr Surg"},{"issue":"4S","key":"1336_CR56","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1016\/j.juro.2009.03.007","volume":"182","author":"ML Capitanucci","year":"2009","unstructured":"Capitanucci ML, Camanni D, Demelas F, Mosiello G, Zaccara A, De Gennaro M. Long-Term Efficacy of Percutaneous Tibial Nerve Stimulation for Different Types of Lower Urinary Tract Dysfunction in Children. J Urol. 2009;182(4S):2056\u201361. https:\/\/doi.org\/10.1016\/j.juro.2009.03.007.","journal-title":"J Urol"},{"issue":"5","key":"1336_CR57","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/01.ju.0000119961.58222.86","volume":"171","author":"M De Gennaro","year":"2004","unstructured":"De Gennaro M, Capitanucci ML, Mastracci P, Silveri M, Gatti C, Mosiello G. Percutaneous Tibial Nerve Neuromodulation is Well Tolerated in Children and Effective for Treating Refractory Vesical Dysfunction. J Urol. 2004;171(5):1911\u20133. https:\/\/doi.org\/10.1097\/01.ju.0000119961.58222.86.","journal-title":"J Urol"},{"issue":"8","key":"1336_CR58","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1002\/nau.24155","volume":"38","author":"K Dombek","year":"2019","unstructured":"Dombek K, Costa Monteiro LM, Fontes JM, Ramos EG. Immediate effect of transcutaneous electrical nerve stimulation on urodynamic parameters of children with myelomeningocele. Neurourol Urodyn. 2019;38(8):2351\u20138. https:\/\/doi.org\/10.1002\/nau.24155.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"1336_CR59","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/nau.25628","volume":"44","author":"\u00d6 \u00d6zdemir Ayla","year":"2025","unstructured":"\u00d6zdemir Ayla \u00d6, \u00d6zel \u015eK, Acar G, Alata\u015f \u0130. Does Adding TENS to Pelvic Floor Rehabilitation Effect on Urodynamics and Clinical Results in Children With Spina Bifida? Neurourol Urodyn. 2025;44(2):451\u20137. https:\/\/doi.org\/10.1002\/nau.25628.","journal-title":"Neurourol Urodyn"},{"issue":"4","key":"1336_CR60","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ucl.2018.06.005","volume":"45","author":"JD Roth","year":"2018","unstructured":"Roth JD, Cain MP. Neuropathic Bladder and Augmentation Cystoplasty. Urol Clin North Am. 2018;45(4):571\u201385. https:\/\/doi.org\/10.1016\/j.ucl.2018.06.005.","journal-title":"Urol Clin North Am"},{"issue":"5","key":"1336_CR61","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1097\/JU.0000000000002239","volume":"206","author":"DA Ginsberg","year":"2021","unstructured":"Ginsberg DA, Boone TB, Cameron AP, Gousse A, Kaufman MR, Keays E, et al. The AUA\/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction: Treatment and Follow-up. J Urol. 2021;206(5):1106\u201313. https:\/\/doi.org\/10.1097\/JU.0000000000002239.","journal-title":"J Urol"},{"issue":"12","key":"1336_CR62","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1007\/s00345-019-02919-z","volume":"38","author":"PJ Cheng","year":"2020","unstructured":"Cheng PJ, Myers JB. Augmentation cystoplasty in the patient with neurogenic bladder. World J Urol. 2020;38(12):3035\u201346. https:\/\/doi.org\/10.1007\/s00345-019-02919-z.","journal-title":"World J Urol"},{"issue":"1","key":"1336_CR63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0090-4295(96)00503-1","volume":"49","author":"PR Monti","year":"1997","unstructured":"Monti PR, Lara RC, Dutra MA, De Carvalho JR. New techniques for construction of efferent conduits based on the mitrofanoff principle. Urology. 1997;49(1):112\u20135. https:\/\/doi.org\/10.1016\/S0090-4295(96)00503-1.","journal-title":"Urology"},{"issue":"3","key":"1336_CR64","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S0022-5347(17)35625-2","volume":"150","author":"WH Yang","year":"1993","unstructured":"Yang WH. Yang Needle Tunneling Technique in Creating Antireflux and Continent Mechanisms. J Urol. 1993;150(3):830\u20134. https:\/\/doi.org\/10.1016\/S0022-5347(17)35625-2.","journal-title":"J Urol"},{"issue":"4","key":"1336_CR65","first-page":"297","volume":"21","author":"P Mitrofanoff","year":"1980","unstructured":"Mitrofanoff P. [Trans-appendicular continent cystostomy in the management of the neurogenic bladder]. Chir Pediatr. 1980;21(4):297\u2013305. PubMed PMID: 7408090.","journal-title":"Chir Pediatr"},{"issue":"4","key":"1336_CR66","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.juro.2013.04.075","volume":"190","author":"BJ Schlomer","year":"2013","unstructured":"Schlomer BJ, Saperston K, Baskin L. National Trends in Augmentation Cystoplasty in the 2000s and Factors Associated with Patient Outcomes. J Urol. 2013;190(4):1352\u20138. https:\/\/doi.org\/10.1016\/j.juro.2013.04.075.","journal-title":"J Urol"},{"issue":"4S","key":"1336_CR67","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/S0022-5347(06)00615-X","volume":"176","author":"TS Lendvay","year":"2006","unstructured":"Lendvay TS, Cowan CA, Mitchell MM, Joyner BD, Grady RW. Augmentation Cystoplasty Rates at Children\u2019s Hospitals in the United States: A Pediatric Health Information System Database Study. J Urol. 2006;176(4S):1716\u201320. https:\/\/doi.org\/10.1016\/S0022-5347(06)00615-X.","journal-title":"J Urol"},{"key":"1336_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.urology.2020.04.080","volume":"142","author":"A Rehfuss","year":"2020","unstructured":"Rehfuss A, Apfeld JC, Sebasti\u00e3o YV, McLeod DJ, Fuchs M, Dajusta D. Utilization of Augmentation Cystoplasty for Myelomeningocele Patients Remained Stable Over the Past Decade. Urology. 2020;142:195\u20139. https:\/\/doi.org\/10.1016\/j.urology.2020.04.080.","journal-title":"Urology"},{"issue":"6","key":"1336_CR69","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/nau.25219","volume":"42","author":"B Li","year":"2023","unstructured":"Li B, Peard LM, Zhao S, Graham MK, Adams C, Taylor AS, et al. Understanding factors influencing primary treatment with intradetrusor onabotulinumtoxinA versus augmentation cystoplasty in patients with spina bifida. Neurourol Urodyn. 2023;42(6):1431\u20136. https:\/\/doi.org\/10.1002\/nau.25219.","journal-title":"Neurourol Urodyn"},{"issue":"4S","key":"1336_CR70","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0022-5347(06)00620-3","volume":"176","author":"AD Parekh","year":"2006","unstructured":"Parekh AD, Trusler LA, Pietsch JB, Byrne DW, DeMarco RT, Pope JC, et al. Prospective, Longitudinal Evaluation of Health Related Quality of Life in the Pediatric Spina Bifida Population Undergoing Reconstructive Urological Surgery. J Urol. 2006;176(4S):1878\u201382. https:\/\/doi.org\/10.1016\/S0022-5347(06)00620-3.","journal-title":"J Urol"},{"issue":"5","key":"1336_CR71","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jpeds.2012.10.042","volume":"162","author":"NL Young","year":"2013","unstructured":"Young NL, Sheridan K, Burke TA, Mukherjee S, McCormick A. Health Outcomes among Youths and Adults with Spina Bifida. J Pediatr. 2013;162(5):993\u20138. https:\/\/doi.org\/10.1016\/j.jpeds.2012.10.042.","journal-title":"J Pediatr"},{"key":"1336_CR72","doi-asserted-by":"publisher","unstructured":"Sawin KJ, Brei TJ, Houtrow AJ. Quality of life: Guidelines for the care of people with spina bifida. Brei T, Castillo H, Castillo J, editors. PRM. 2020;13(4):565\u201382. https:\/\/doi.org\/10.3233\/PRM-200732","DOI":"10.3233\/PRM-200732"},{"issue":"10","key":"1336_CR73","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s11136-015-0988-5","volume":"24","author":"KM Szymanski","year":"2015","unstructured":"Szymanski KM, Misseri R, Whittam B, Raposo SM, King SJ, Kaefer M, et al. QUAlity of Life Assessment in Spina bifida for Adults (QUALAS-A): development and international validation of a novel health-related quality of life instrument. Qual Life Res. 2015;24(10):2355\u201364. https:\/\/doi.org\/10.1007\/s11136-015-0988-5.","journal-title":"Qual Life Res"},{"issue":"3","key":"1336_CR74","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5173\/ceju.2017.1195","volume":"70","author":"KM Szyma\u0144ski","year":"2017","unstructured":"Szyma\u0144ski KM, Misseri R, Whittam B, Casey JT, Yang DY, Raposo SM, et al. Validation of QUALAS-T, a health-related quality of life instrument for teenagers with spina bifida. Cent Eur J Urol. 2017;70(3):306\u201313. https:\/\/doi.org\/10.5173\/ceju.2017.1195. PubMed PMID: 29104796; PubMed Central PMCID: PMC5656361.","journal-title":"Cent Eur J Urol"},{"key":"1336_CR75","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.urology.2015.09.027","volume":"87","author":"KM Szymanski","year":"2016","unstructured":"Szymanski KM, Misseri R, Whittam B, Yang DY, Raposo SM, King SJ, et al. Quality of Life Assessment in Spina Bifida for Children (QUALAS-C): Development and Validation of a Novel Health-related Quality of Life Instrument. Urology. 2016;87:178\u201384. https:\/\/doi.org\/10.1016\/j.urology.2015.09.027.","journal-title":"Urology"},{"issue":"6","key":"1336_CR76","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1080\/10790268.2024.2420141","volume":"48","author":"N Younsi","year":"2025","unstructured":"Younsi N, Stein R, Szymanski KM. Adaptation of the German language version of the QUAlity of life assessment of spina bifida for adults (QUALAS-A-G). J Spinal Cord Med. 2025;48(6):1140\u20135. https:\/\/doi.org\/10.1080\/10790268.2024.2420141.","journal-title":"J Spinal Cord Med"},{"key":"1336_CR77","doi-asserted-by":"publisher","unstructured":"Kawahara T, Momose H, Sugita Y, Szymanski KM, Hida E, Yamazaki A. Translation, cultural adaptation, and validation of the Japanese version of the quality of life assessment in spina bifida for adults. J Patient Rep Outcomes. 2026. https:\/\/doi.org\/10.1186\/s41687-026-01018-z.","DOI":"10.1186\/s41687-026-01018-z"},{"issue":"5","key":"1336_CR78","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/ijerph21050624","volume":"21","author":"M Dellenmark-Blom","year":"2024","unstructured":"Dellenmark-Blom M, Andersson M, Szymanski KM, Andr\u00e9asson CL, Vu Minh Arnell M, Sj\u00f6str\u00f6m S, et al. Linguistic, Content and Face Validity of the Swedish Version of a Quality-of-Life Assessment for Children, Teenagers and Adults with Spina Bifida. IJERPH. 2024;21(5):624. https:\/\/doi.org\/10.3390\/ijerph21050624.","journal-title":"IJERPH"},{"issue":"9","key":"1336_CR79","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1080\/09638288.2023.2207222","volume":"46","author":"H Yun","year":"2024","unstructured":"Yun H, Yang SH, Ji Y, Kim SW, Bae E, Park J, et al. Cross-cultural adaptation and validation of the Korean version of the quality of life assessment in spina bifida for children (QUALAS-C-K). Disabil Rehabil. 2024;46(9):1898\u2013903. https:\/\/doi.org\/10.1080\/09638288.2023.2207222.","journal-title":"Disabil Rehabil"},{"issue":"3 Part 2","key":"1336_CR80","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.juro.2016.08.117","volume":"197","author":"KM Szymanski","year":"2017","unstructured":"Szymanski KM, Cain MP, Whittam B, Kaefer M, Rink RC, Misseri R. All Incontinence is Not Created Equal: Impact of Urinary and Fecal Incontinence on Quality of Life in Adults with Spina Bifida. J Urol. 2017;197(3 Part 2):885\u201391. https:\/\/doi.org\/10.1016\/j.juro.2016.08.117.","journal-title":"J Urol"},{"issue":"4","key":"1336_CR81","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jpurol.2024.03.013","volume":"20","author":"AW Johnston","year":"2024","unstructured":"Johnston AW, Misseri R, Cordero NS, Koehlinger J, Stanley K, Trinh A, et al. Parental decision regret after pediatric urologic surgeries compared to decisions of everyday life. J Pediatr Urol. 2024;20(4):742. .e1-742.e9.","journal-title":"J Pediatr Urol"},{"issue":"2","key":"1336_CR82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jpurol.2017.11.012","volume":"14","author":"KM Szymanski","year":"2018","unstructured":"Szymanski KM, Whittam B, Kaefer M, Frady H, Casey JT, Tran VT, et al. Parental decisional regret and views about optimal timing of female genital restoration surgery in congenital adrenal hyperplasia. J Pediatr Urol. 2018;14(2):156. https:\/\/doi.org\/10.1016\/j.jpurol.2017.11.012.","journal-title":"J Pediatr Urol"},{"issue":"4","key":"1336_CR83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0272989X03256005","volume":"23","author":"JC Brehaut","year":"2003","unstructured":"Brehaut JC, O\u2019Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Mak. 2003;23(4):281\u201392. https:\/\/doi.org\/10.1177\/0272989X03256005. PubMed PMID: 12926578.","journal-title":"Med Decis Mak"},{"issue":"4","key":"1336_CR84","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/JU.0000000000004643","volume":"214","author":"NV Batra","year":"2025","unstructured":"Batra NV, Johnston AW, Cain MP, Dangle PP, Kaefer M, Meldrum KK, et al. Evaluating Decisional Regret in Adults With Spina Bifida Regarding Childhood Surgeries for Neurogenic Bladder and Bowel. J Urol. 2025;214(4):426\u201334. https:\/\/doi.org\/10.1097\/JU.0000000000004643.","journal-title":"J Urol"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-026-01336-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-026-01336-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:34:57Z","timestamp":1776134097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-026-01336-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1336"],"URL":"https:\/\/doi.org\/10.1007\/s11934-026-01336-1","relation":{},"ISSN":["1534-6285"],"issn-type":[{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}